Key result
A multimodal drug effort combining RAAS inhibitors with SGLT2 inhibitors or finerenone is needed to achieve maximum kidney and cardiovascular protection in patients with CKD and T2DM.
Why the study?
Slowing progression is an important therapeutic goal in CKD associated with T2DM, requiring a review of kidney and CV protective effects of ACEIs and ARBs alone or in combination therapies.
Does multimodal drug therapy improve kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus?
Does multimodal drug therapy improve kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus?
Highlights the necessity of a multimodal pharmacological approach, including RAAS inhibitors, SGLT2 inhibitors, and finerenone, to maximize cardiovascular and kidney protection in patients with diabetic kidney disease.
Answers are grounded in this paper and cite their sources.
May support multimodal therapy consideration in diabetic CKD; leaves open optimal regimens pending dedicated RCTs.
In patients with chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM), slowing kidney disease progression is an important therapeutic goal. Many patients with T2DM and CKD also have cardiovascular (CV) comorbidities. Renin-angiotensin-aldosterone system inhibitors (RAASis), which include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are drugs with known antihypertensive effects as well as CV and kidney protective effects in patients with CKD. Studies have shown that adding a sodium-glucose cotransporter-2 (SGLT2) inhibitor to ACEI or ARB therapy has additive benefits in terms of kidney and CV protection in patients with CKD (with/without T2DM). For patients with CKD associated with T2DM who have persistent albuminuria despite taking the maximum tolerated dose of a RAASi, adding a nonsteroidal mineralocorticoid receptor antagonist (finerenone) has demonstrated CV and kidney benefits in clinical trials. In this article, we review the use of ACEIs and ARBs for their kidney and CV protective effects when used alone or in combination with a drug with a different mechanism of action. From reviewing the available evidence, it seems clear that a multimodal drug effort is needed to achieve maximum kidney and CV protective effects for patients with CKD associated with T2DM.
No takes yet. Share an insight, caveat, or question.
Rastogi et al. (2023) conducted a review in Chronic kidney disease associated with type 2 diabetes mellitus. Multimodal drug therapy (RAAS inhibitors, SGLT2 inhibitors, finerenone) was evaluated. A multimodal drug effort combining RAAS inhibitors with SGLT2 inhibitors or finerenone is needed to achieve maximum kidney and cardiovascular protection in patients with CKD and T2DM.
Synapse has enriched 10 related papers. Consider them for comparative context: